论文部分内容阅读
为探讨马法兰、环磷酰胺和阿糖胞苷（ＭＡＣ）预处理自体骨髓移植（ＡＢＭＴ）治疗不同类型白血病的疗效，比较了１５例急性髓细胞白血病（ＡＭＬ）和９例急性淋巴细胞白血病（ＡＬＬ）用ＭＡＣ方案预处理ＡＢＭＴ的疗效。结果：ＭＡＣ方案对两类急性白血病患者均有明显的造血抑制及抗白血病作用。ＭＡＣ方案作预处理ＡＢＭＴ后ＡＭＬ患者比ＡＬＬ患者复发率低，生存期长［２４（３～６２）个月ｖｓ１４（１～２６）个月］。提示：ＭＡＣ预处理方案适用于ＡＭＬ患者，而对ＡＬＬ患者作ＡＢＭＴ需调整或改换其它方案。
To investigate the efficacy of maflan, cyclophosphamide and cytarabine (MAC) pretreatment autologous bone marrow transplantation (ABMT) in the treatment of different types of leukemia, 15 cases of acute myeloid leukemia (AML) and 9 cases of acute lymphoblastic leukemia (ALL) were compared. ) Pretreatment of ABMT with the MAC regimen. RESULTS: The MAC regimen had significant hematopoietic inhibition and anti-leukemia effects on both types of acute leukemia patients. After the pretreatment of ABMT with MAC protocol, the relapse rate of AML patients is lower than that of ALL patients and the survival period is long [24(3~62) months vs14(1~26) months]. Tip: The MAC pretreatment program is applicable to AML patients, while ABMT for ALL patients needs to be adjusted or replaced by other programs.